Antibody Mediated Rejection clinical trials at University of California Health
4 in progress, 1 open to eligible people
Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)
open to eligible people ages 18-75
The main goal of this trial is to evaluate the efficacy of felzartamab compared to placebo in kidney transplant recipients diagnosed with late active or chronic active AMR.
at UCLA
BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)
Sorry, in progress, not accepting new patients
Primary Objectives: - Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR - Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: - To assess the overall efficacy of BIVV020 in prevention or treatment of AMR - To characterize the safety and tolerability of BIVV020 in kidney transplant participants - To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant participants - To evaluate the immunogenicity of BIVV020
at UCLA UCSF
ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Sorry, in progress, not accepting new patients
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
at UCLA
VIRTUUS Children's Study
Sorry, in progress, not accepting new patients
The objective of the VIRTUUS Children's Study is to adapt identified and validated adult noninvasive diagnostic and prognostic biomarkers for the characterization of allograft status in pediatric recipients of kidney allografts.
at UCLA UCSD
Our lead scientists for Antibody Mediated Rejection research studies include Suphamai Bunnapradist, MD, MS.
Last updated: